Recurrent Breast Cancer, Stage IV Breast Cancer
Conditions
Brief summary
Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estradiol can cause the growth of breast cancer. Hormone therapy using anastrozole may fight breast cancer by blocking the use of estradiol by the tumor cells. Sometimes when hormone therapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant to hormone therapy. Giving sorafenib together with anastrozole may reduce drug resistance and allow the tumor cells to be killed. This phase I/II trial is studying the side effects and best dose of sorafenib when given in combination with anastrozole and to see how well they work in treating postmenopausal women with metastatic breast cancer.
Detailed description
PRIMARY OBJECTIVES: I. Determine the clinical benefit rate of sorafenib in combination with anastrazole in women with estrogen receptor- and/or progesterone receptor-positive metastatic breast cancer. II. Determine the recommended phase II dose of sorafenib when administered with anastrozole in these patients. SECONDARY OBJECTIVES: I. Determine the toxic effects of this regimen in these patients. II. Determine the changes in Raf-MAPK and VEGF-signaling pathways in tumor tissue and stroma before and after treatment with this regimen in these patients. OUTLINE: This is a multicenter, dose-escalation study of sorafenib. PHASE I: Patients receive oral sorafenib twice daily and oral anastrozole once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD. PHASE II: Patients receive sorafenib at the MTD and anastrozole as in phase I. After completion of study treatment, patients are followed every 4-8 weeks.
Interventions
DRUGsorafenib tosylate
Given orally
DRUGanastrozole
Given orally
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed breast cancer * Metastatic disease * Measurable disease, defined as \>=1 unidimensionally measurable lesion, including \>= 1 of the following: * Lesion \>= 10 mm on CT scan (5 mm sections) * Lesion \>= 20 mm on CT scan or MRI (10 mm sections) * Bone disease that is \>= 10 mm on MRI * Lytic bone lesions that are \>= 10 mm on CT scan (with 5 mm sections) OR \>= 20 mm on plain film or CT scan (with 10 mm sections) * Lesion \>= 10 mm on physical exam * Patients must have received \>= 1 prior aromatase inhibitor in either the adjuvant or metastatic setting and must have had either disease recurrence or disease progression on a prior aromatase inhibitor therapy * No brain metastases diagnosed within the past 6 months OR previously untreated brain metastases * Estrogen receptor-positive and/or progesterone receptor-positive, defined as \> 1% staining by immunohistochemistry or \> 10 fmol/mg of protein by radio-ligand dextran-coated steroid binding assay * Postmenopausal, as defined by 1 of the following: * Prior bilateral oophorectomy * No menses for \>= 12 months in patients with an intact uterus * Follicle-stimulating hormone (FSH) in postmenopausal range in patients \< 60 years of age who have had a prior hysterectomy or have been amenorrheic for \>= 3 months * Age \>= 60 years * Pre- or perimenopausal patients receiving monthly injections of goserelin at a dose of 3.6 mg are eligible * ECOG 0-2 * More than 3 months * Absolute neutrophil count \>= 1,500/mm3 Platelet count \>= 100,000/mm3 No bleeding diathesis * Bilirubin =\< 1.5 times upper limit of normal (ULN AST and ALT =\< 2.5 times ULN * Systolic blood pressure (BP) \< 150 mm Hg and diastolic BP \< 100 mm Hg on at least one reading prior to study entry No uncontrolled hypertension * None of the following within the past 6 months: * Symptomatic congestive heart failure * Unstable angina pectoris * Myocardial infarction * Cardiac arrhythmia with hemodynamic compromise * Not pregnant or nursing * Able to swallow oral medication * No known HIV positivity * No ongoing or active infection * No psychiatric illness or social situation that would preclude study compliance * No other active invasive malignancy within the past 5 years except nonmelanoma skin cancer or treated carcinoma in situ of the cervix * No other uncontrolled illness * More than 4 weeks since prior chemotherapy * No more than 2 prior chemotherapy regimens for metastatic disease * At least 8 weeks since prior anastrozole therapy * Concurrent steroids allowed if dose is stable * More than 4 weeks since prior radiotherapy * More than 4 weeks since prior major surgery * Recovered from prior therapy * No prior sorafenib * No concurrent therapeutic anticoagulation * Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided PT and PTT are =\< 1.5 times ULN * No concurrent agents that may interact with sorafenib, including any of the following: * Hypericum perforatum (St. John's wort) * Rifampin * P450 CYP3A4 enzyme-inducing anticonvulsants (e.g., phenytoin, carbamazepine, or phenobarbital) * No other concurrent investigational agents
Exclusion criteria
* estrogen receptor status unknown * history of myocardial infarction within 6 months * performance status 3 * performance status 4 * premenopausal * progesterone receptor status unknown * HIV positive
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response + Partial Response + Stable Disease > 24 Weeks | 24 weeks | Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking. A patient has clinical benefit from treatment if CR + PR + SD \> 24 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Adverse Events | 1 year | Number of patients treated with the sorafenib / anastrozole combination who experienced Grade 1-4 adverse events according to NCI common terminology criteria for adverse events (CTCAE) version 3.0 |
| Tumor Marker Analysis | 1 year | Number of participants with significant change in the following circulating tumor biomarkers, measured by flow cytometry: cluster designation (CD)146, CD133. Values were normalized by CD45 values(ie CD146+/CD45- and CD133+/CD45-). |
Countries
United States
Participant flow
Recruitment details
Subjects were recruited from 22-Sep-2005 through 01-Jul-2009
Participants by arm
| Arm | Count |
|---|---|
| Sorafenib and Anastrozole A single arm of 35 patients with advanced or metastatic breast cancer receiving a combination of sorafenib and anastrozole. | 35 |
| Total | 35 |
Baseline characteristics
| Characteristic | Sorafenib and Anastrozole |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 5 Participants |
| Age, Categorical Between 18 and 65 years | 30 Participants |
| Age, Continuous | 55 years STANDARD_DEVIATION 30 |
| Region of Enrollment United States | 35 participants |
| Sex: Female, Male Female | 35 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 35 / 35 |
| serious Total, serious adverse events | 12 / 35 |
Outcome results
Primary
Complete Response + Partial Response + Stable Disease > 24 Weeks
Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking. A patient has clinical benefit from treatment if CR + PR + SD \> 24 weeks.
Time frame: 24 weeks
Population: Female patients with advanced or metastatic breast cancer. The protocol was initiated with intention to treat every patient enrolled with a sorafenib and anastrozole combination.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Sorafenib and Anastrozole | Complete Response + Partial Response + Stable Disease > 24 Weeks | 35 participants |
Secondary
Number of Participants With Adverse Events
Number of patients treated with the sorafenib / anastrozole combination who experienced Grade 1-4 adverse events according to NCI common terminology criteria for adverse events (CTCAE) version 3.0
Time frame: 1 year
Population: All 35 patients enrolled in the study were assessed for adverse events according to NCI common terminology criteria for adverse events (CTCAE) version 3.0.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Sorafenib and Anastrozole | Number of Participants With Adverse Events | 35 participants |
Secondary
Tumor Marker Analysis
Number of participants with significant change in the following circulating tumor biomarkers, measured by flow cytometry: cluster designation (CD)146, CD133. Values were normalized by CD45 values(ie CD146+/CD45- and CD133+/CD45-).
Time frame: 1 year
Population: 14 subjects had blood specimens available for analysis
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Sorafenib and Anastrozole | Tumor Marker Analysis | 14 participants |